BioNTech Small Molecules GmbH i.Gr.

BioNTech Small Molecules is a newly founded wholly owned subsidiary of BioNTech AG, Mainz. The purchase price for the assets to be transferred directly to BioNTech Small Molecules amounts to EUR 650 thousand. In addition, 4SC receives the right to use research services of BioNTech Small Molecules for a limited period of time in the equivalent of one person-year without financial consideration. As of May 1, 2016, all 22 employees of 4SC Discovery will be taken over as part of a transfer of operations and will continue to work at the previous site in Planegg-Martinsried. Among other things, the internally developed 4SCan(R) software for drug discovery and optimization, the property, plant and equipment and the substance libraries of 4SC Discovery will be transferred. The other intangible assets are not affected by this transaction.